WCPT 820 Interview: Joe Cunningham of Pharmaceutical Reform Alliance

Richard Chew is joined by Joe Cunningham, former congressman who now serves as spokesperson for the Pharmaceutical Reform Alliance; he discusses PRA’s new report on big pharma and drug prices. They discuss political leadership, economic affordability, and the necessity of pharmaceutical reform.

Joe Cunningham's Background
- Joe Cunningham is a Democratic politician from Charleston, South Carolina, who previously served in a district (South Carolina's 1st Congressional District) that had not elected a Democrat in almost 40 years.
- He was part of the 2018 freshman class of leadership and later ran as the Democratic nominee for governor of South Carolina in 2022.

Political Momentum and Challenges
- Cunningham argues that current economic hardships and failed policies have created a growing frustration among Americans.
- He highlights the disparity between government spending on things like D.C. infrastructure and the struggles citizens face with rent and groceries.
- The discussion touches on the need for new generational leadership to address these systemic issues.

Affordability and Accountability
- Chew and Cunningham discuss how affordability and accountability are deeply interconnected in the minds of voters.
- Cunningham notes that frustration grows when people see government officials profiting from stock trades or misusing funds while citizens struggle.

Democratic Party Opportunities
- Cunningham suggests the Democratic Party needs to rebuild credibility by speaking directly to voters rather than talking down to them.
- He advocates for moving beyond just criticizing opponents and instead presenting bold, New Deal-style ideas to uplift Americans.
- The conversation emphasizes the importance of being results-driven rather than focusing solely on political accountability.

Prescription Drug Pricing Reform
- Cunningham explains that Americans pay roughly three times more for prescription drugs than people in other developed nations.
- He promotes the "most favored nation" policy, which aims to bring U.S. drug prices in line with global averages.
- This specific policy reportedly enjoys high bipartisan support, including interest from both Democrats and some Republicans like Marjorie Taylor Greene.

Big Pharma Lobbying Influence
- The discussion highlights how the pharmaceutical industry uses massive amounts of money to lobby Congress and block price reform.
- Cunningham points out that some conservative groups receive significant funding from pharmaceutical trade associations to oppose drug pricing legislation.
- High costs lead to a compounding strain on the health care system as patients skip doses or delay necessary care due to expense.

Future Outlook for Healthcare Reform
- Cunningham notes that while accountability is important, the party must also deliver tangible results like lower health care costs.
- He mentions the rising popularity of GLP medications but emphasizes that their benefits are limited by high price tags in the U.S. compared to Japan or The Netherlands.
- The segment concludes with an emphasis on using potential legislative wins in future elections to drive meaningful pharmaceutical reform.